Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial
Background: Vortioxetine and venlafaxine are antidepressants which have shown established efficacy to treat major depressive disorder (MDD). There are no studies that compared them for their efficacy in cognitive symptoms of depression. The study aimed to compare the effect of vortioxetine and venla...
Gespeichert in:
| Veröffentlicht in: | Indian journal of psychiatry 2023-08, Vol.65 (8), p.815-824 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 824 |
|---|---|
| container_issue | 8 |
| container_start_page | 815 |
| container_title | Indian journal of psychiatry |
| container_volume | 65 |
| creator | Manna, Chayan Ranjan, Rajeev Kumar, Pankaj Ahmad, Shamshad Nath, Santanu |
| description | Background: Vortioxetine and venlafaxine are antidepressants which have shown established efficacy to treat major depressive disorder (MDD). There are no studies that compared them for their efficacy in cognitive symptoms of depression. The study aimed to compare the effect of vortioxetine and venlafaxine on the change in cognitive scores in adults with MDD.
Methods: The present study was an open-label, active-controlled parallel design randomized clinical trial. After randomization, baseline clinical evaluations by Montgomery-Asberg Depression Rating Scale (MADRS) and Social and Occupational Functioning Assessment Scale (SOFAS) were done and coding (subset of WAIS-IV), WCST, TMT, Stroop test, PGI memory were used to assess cognition in 100 unmedicated MDD patients. They were reassessed after eight weeks of monotherapy with vortioxetine or venlafaxine.
Results: Primary cognitive measure (coding score) was found to be significantly higher (Mean Difference = 0.680; 95% CI:.202 to 1.158; P = 0.006) in vortioxetine in comparison with venlafaxine. Stroop test scores (word score, color score, color-word score) were also found to be significantly higher with vortioxetine. In other cognitive measures (WCST scores: total trials, total errors score, total perseverative responses score, total perseverative errors scores; TMT-A and B scores), a significant decrease in scores with vortioxetine in comparison with venlafaxine were observed. A significant decrease in MADRS and increase in SOFAS scores were observed with vortioxetine in comparison with venlafaxine. Both the drugs alleviated the symptoms of depression but vortioxetine was better tolerated.
Conclusion: Our study findings suggest that improvement in cognitive scores is significantly higher with vortioxetine than venlafaxine over the eight weeks of monotherapy.
Clinical Trial registration number: CTRI/2020/07/026819 (Registered with Clinical Trials Registry- India). |
| doi_str_mv | 10.4103/indianjpsychiatry.indianjpsychiatry_160_23 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10510634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A763383627</galeid><sourcerecordid>A763383627</sourcerecordid><originalsourceid>FETCH-LOGICAL-c799e-eace505733fcb0337520b773c43e80bc734a085b112ff7e84b6646523438cbe13</originalsourceid><addsrcrecordid>eNqdk9-OEyEUhydGE2v1HUhMjDetMMAM443ZbNZ_2cQbvSYMc2jpMlBhpt31CXxsqV21dbUxhguSMx8fDIdfUZQEzxnB9IX1nVV-tU43emnVEG_mdyqSVFiW9F4xIU0jZrRu2P1igjFpZpwz_rB4lNIK47JivJ4UXy-MAT2gYNAmxMGGaxisB7SBmMaUJ--UUde7UvBIh4W3g90AMqPXmfYJWY9UN7ohoa0dlqhXqxBRB-sIKe3IzqYQO4gv0RmKyneht1-gm-nghxicgw4N0Sr3uHhglEvw5HaeFp9eX3w8fzu7_PDm3fnZ5UzXTQMzUBo45jWlRreY0pqXuK1rqhkFgVtdU6aw4C0hpTE1CNZWFat4SRkVugVCp8WrvXc9tj10GvIxlJPraHuVLy8oK4-_eLuUi7CRBHOCq-yZFs9vDTF8HiENsrdJg3PKQxiTLEUlCBGciYw-_Q1dhTH6_H-SEkIYo6xsTlHZhXlFeFn-ohbKgbTehHw8vdtangkicE1LcpqqK0oFrco6U_M_UHl00NvcGTA214-0_7TgcIdnBwuWoNywTMGN39_MsfkkeGh8vwd1DClFMD97RrDchUPejcLfwpFlZi_bBjfkp37lxi1Emdt-5cP2P4xSEC73WZLByB9Zot8AQB83Ig</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2860561522</pqid></control><display><type>article</type><title>Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial</title><source>Medknow Open Access Medical Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Manna, Chayan ; Ranjan, Rajeev ; Kumar, Pankaj ; Ahmad, Shamshad ; Nath, Santanu</creator><creatorcontrib>Manna, Chayan ; Ranjan, Rajeev ; Kumar, Pankaj ; Ahmad, Shamshad ; Nath, Santanu</creatorcontrib><description>Background: Vortioxetine and venlafaxine are antidepressants which have shown established efficacy to treat major depressive disorder (MDD). There are no studies that compared them for their efficacy in cognitive symptoms of depression. The study aimed to compare the effect of vortioxetine and venlafaxine on the change in cognitive scores in adults with MDD.
Methods: The present study was an open-label, active-controlled parallel design randomized clinical trial. After randomization, baseline clinical evaluations by Montgomery-Asberg Depression Rating Scale (MADRS) and Social and Occupational Functioning Assessment Scale (SOFAS) were done and coding (subset of WAIS-IV), WCST, TMT, Stroop test, PGI memory were used to assess cognition in 100 unmedicated MDD patients. They were reassessed after eight weeks of monotherapy with vortioxetine or venlafaxine.
Results: Primary cognitive measure (coding score) was found to be significantly higher (Mean Difference = 0.680; 95% CI:.202 to 1.158; P = 0.006) in vortioxetine in comparison with venlafaxine. Stroop test scores (word score, color score, color-word score) were also found to be significantly higher with vortioxetine. In other cognitive measures (WCST scores: total trials, total errors score, total perseverative responses score, total perseverative errors scores; TMT-A and B scores), a significant decrease in scores with vortioxetine in comparison with venlafaxine were observed. A significant decrease in MADRS and increase in SOFAS scores were observed with vortioxetine in comparison with venlafaxine. Both the drugs alleviated the symptoms of depression but vortioxetine was better tolerated.
Conclusion: Our study findings suggest that improvement in cognitive scores is significantly higher with vortioxetine than venlafaxine over the eight weeks of monotherapy.
Clinical Trial registration number: CTRI/2020/07/026819 (Registered with Clinical Trials Registry- India).</description><identifier>ISSN: 0019-5545</identifier><identifier>EISSN: 1998-3794</identifier><identifier>DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_160_23</identifier><language>eng</language><publisher>Mysore: Wolters Kluwer India Pvt. Ltd</publisher><subject>Adults ; Antidepressants ; Clinical trials ; Cognition ; Cognitive ability ; Comparative analysis ; Major depressive disorder ; Medical research ; Medicine, Experimental ; Mental depression ; Original ; Product development ; Venlafaxine</subject><ispartof>Indian journal of psychiatry, 2023-08, Vol.65 (8), p.815-824</ispartof><rights>COPYRIGHT 2023 Medknow Publications and Media Pvt. Ltd.</rights><rights>2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2023 Indian Journal of Psychiatry 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c799e-eace505733fcb0337520b773c43e80bc734a085b112ff7e84b6646523438cbe13</citedby><cites>FETCH-LOGICAL-c799e-eace505733fcb0337520b773c43e80bc734a085b112ff7e84b6646523438cbe13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510634/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510634/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27435,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Manna, Chayan</creatorcontrib><creatorcontrib>Ranjan, Rajeev</creatorcontrib><creatorcontrib>Kumar, Pankaj</creatorcontrib><creatorcontrib>Ahmad, Shamshad</creatorcontrib><creatorcontrib>Nath, Santanu</creatorcontrib><title>Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial</title><title>Indian journal of psychiatry</title><description>Background: Vortioxetine and venlafaxine are antidepressants which have shown established efficacy to treat major depressive disorder (MDD). There are no studies that compared them for their efficacy in cognitive symptoms of depression. The study aimed to compare the effect of vortioxetine and venlafaxine on the change in cognitive scores in adults with MDD.
Methods: The present study was an open-label, active-controlled parallel design randomized clinical trial. After randomization, baseline clinical evaluations by Montgomery-Asberg Depression Rating Scale (MADRS) and Social and Occupational Functioning Assessment Scale (SOFAS) were done and coding (subset of WAIS-IV), WCST, TMT, Stroop test, PGI memory were used to assess cognition in 100 unmedicated MDD patients. They were reassessed after eight weeks of monotherapy with vortioxetine or venlafaxine.
Results: Primary cognitive measure (coding score) was found to be significantly higher (Mean Difference = 0.680; 95% CI:.202 to 1.158; P = 0.006) in vortioxetine in comparison with venlafaxine. Stroop test scores (word score, color score, color-word score) were also found to be significantly higher with vortioxetine. In other cognitive measures (WCST scores: total trials, total errors score, total perseverative responses score, total perseverative errors scores; TMT-A and B scores), a significant decrease in scores with vortioxetine in comparison with venlafaxine were observed. A significant decrease in MADRS and increase in SOFAS scores were observed with vortioxetine in comparison with venlafaxine. Both the drugs alleviated the symptoms of depression but vortioxetine was better tolerated.
Conclusion: Our study findings suggest that improvement in cognitive scores is significantly higher with vortioxetine than venlafaxine over the eight weeks of monotherapy.
Clinical Trial registration number: CTRI/2020/07/026819 (Registered with Clinical Trials Registry- India).</description><subject>Adults</subject><subject>Antidepressants</subject><subject>Clinical trials</subject><subject>Cognition</subject><subject>Cognitive ability</subject><subject>Comparative analysis</subject><subject>Major depressive disorder</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mental depression</subject><subject>Original</subject><subject>Product development</subject><subject>Venlafaxine</subject><issn>0019-5545</issn><issn>1998-3794</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqdk9-OEyEUhydGE2v1HUhMjDetMMAM443ZbNZ_2cQbvSYMc2jpMlBhpt31CXxsqV21dbUxhguSMx8fDIdfUZQEzxnB9IX1nVV-tU43emnVEG_mdyqSVFiW9F4xIU0jZrRu2P1igjFpZpwz_rB4lNIK47JivJ4UXy-MAT2gYNAmxMGGaxisB7SBmMaUJ--UUde7UvBIh4W3g90AMqPXmfYJWY9UN7ohoa0dlqhXqxBRB-sIKe3IzqYQO4gv0RmKyneht1-gm-nghxicgw4N0Sr3uHhglEvw5HaeFp9eX3w8fzu7_PDm3fnZ5UzXTQMzUBo45jWlRreY0pqXuK1rqhkFgVtdU6aw4C0hpTE1CNZWFat4SRkVugVCp8WrvXc9tj10GvIxlJPraHuVLy8oK4-_eLuUi7CRBHOCq-yZFs9vDTF8HiENsrdJg3PKQxiTLEUlCBGciYw-_Q1dhTH6_H-SEkIYo6xsTlHZhXlFeFn-ohbKgbTehHw8vdtangkicE1LcpqqK0oFrco6U_M_UHl00NvcGTA214-0_7TgcIdnBwuWoNywTMGN39_MsfkkeGh8vwd1DClFMD97RrDchUPejcLfwpFlZi_bBjfkp37lxi1Emdt-5cP2P4xSEC73WZLByB9Zot8AQB83Ig</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Manna, Chayan</creator><creator>Ranjan, Rajeev</creator><creator>Kumar, Pankaj</creator><creator>Ahmad, Shamshad</creator><creator>Nath, Santanu</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><general>Wolters Kluwer - Medknow</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230801</creationdate><title>Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial</title><author>Manna, Chayan ; Ranjan, Rajeev ; Kumar, Pankaj ; Ahmad, Shamshad ; Nath, Santanu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c799e-eace505733fcb0337520b773c43e80bc734a085b112ff7e84b6646523438cbe13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adults</topic><topic>Antidepressants</topic><topic>Clinical trials</topic><topic>Cognition</topic><topic>Cognitive ability</topic><topic>Comparative analysis</topic><topic>Major depressive disorder</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mental depression</topic><topic>Original</topic><topic>Product development</topic><topic>Venlafaxine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manna, Chayan</creatorcontrib><creatorcontrib>Ranjan, Rajeev</creatorcontrib><creatorcontrib>Kumar, Pankaj</creatorcontrib><creatorcontrib>Ahmad, Shamshad</creatorcontrib><creatorcontrib>Nath, Santanu</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Indian journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manna, Chayan</au><au>Ranjan, Rajeev</au><au>Kumar, Pankaj</au><au>Ahmad, Shamshad</au><au>Nath, Santanu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial</atitle><jtitle>Indian journal of psychiatry</jtitle><date>2023-08-01</date><risdate>2023</risdate><volume>65</volume><issue>8</issue><spage>815</spage><epage>824</epage><pages>815-824</pages><issn>0019-5545</issn><eissn>1998-3794</eissn><abstract>Background: Vortioxetine and venlafaxine are antidepressants which have shown established efficacy to treat major depressive disorder (MDD). There are no studies that compared them for their efficacy in cognitive symptoms of depression. The study aimed to compare the effect of vortioxetine and venlafaxine on the change in cognitive scores in adults with MDD.
Methods: The present study was an open-label, active-controlled parallel design randomized clinical trial. After randomization, baseline clinical evaluations by Montgomery-Asberg Depression Rating Scale (MADRS) and Social and Occupational Functioning Assessment Scale (SOFAS) were done and coding (subset of WAIS-IV), WCST, TMT, Stroop test, PGI memory were used to assess cognition in 100 unmedicated MDD patients. They were reassessed after eight weeks of monotherapy with vortioxetine or venlafaxine.
Results: Primary cognitive measure (coding score) was found to be significantly higher (Mean Difference = 0.680; 95% CI:.202 to 1.158; P = 0.006) in vortioxetine in comparison with venlafaxine. Stroop test scores (word score, color score, color-word score) were also found to be significantly higher with vortioxetine. In other cognitive measures (WCST scores: total trials, total errors score, total perseverative responses score, total perseverative errors scores; TMT-A and B scores), a significant decrease in scores with vortioxetine in comparison with venlafaxine were observed. A significant decrease in MADRS and increase in SOFAS scores were observed with vortioxetine in comparison with venlafaxine. Both the drugs alleviated the symptoms of depression but vortioxetine was better tolerated.
Conclusion: Our study findings suggest that improvement in cognitive scores is significantly higher with vortioxetine than venlafaxine over the eight weeks of monotherapy.
Clinical Trial registration number: CTRI/2020/07/026819 (Registered with Clinical Trials Registry- India).</abstract><cop>Mysore</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/indianjpsychiatry.indianjpsychiatry_160_23</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0019-5545 |
| ispartof | Indian journal of psychiatry, 2023-08, Vol.65 (8), p.815-824 |
| issn | 0019-5545 1998-3794 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10510634 |
| source | Medknow Open Access Medical Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Adults Antidepressants Clinical trials Cognition Cognitive ability Comparative analysis Major depressive disorder Medical research Medicine, Experimental Mental depression Original Product development Venlafaxine |
| title | Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A25%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20vortioxetine%20versus%20venlafaxine%20on%20cognitive%20functions%20in%20adults%20with%20major%20depressive%20disorder:%20A%20randomized-controlled%20trial&rft.jtitle=Indian%20journal%20of%20psychiatry&rft.au=Manna,%20Chayan&rft.date=2023-08-01&rft.volume=65&rft.issue=8&rft.spage=815&rft.epage=824&rft.pages=815-824&rft.issn=0019-5545&rft.eissn=1998-3794&rft_id=info:doi/10.4103/indianjpsychiatry.indianjpsychiatry_160_23&rft_dat=%3Cgale_pubme%3EA763383627%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2860561522&rft_id=info:pmid/&rft_galeid=A763383627&rfr_iscdi=true |